Company profile NHWK

NightHawk Biosciences Inc
heat biologics is a clinical-stage company focused on developing its proprietary impact™ (immune pan-antigen cytotoxic therapy), a fully allogeneic (“off-the-shelf”) cell-based immunotherapy for use in the treatment of a wide range of cancers. heat's impact therapy is a first-in-class, fully human immunotherapy that functions as both an immune stimulator and an antigen-...delivery system. impact effectively transforms living allogeneic cells into "osmotic pumps" that continuously secrete cancerous antigens to robustly stimulate the immune system against the targeted cancer. impact therapy is applicable to a wide range of cancers. heat is currently conducting two phase 2 clinical trials with its hs-110 to treat non-small cell lung cancer (nsclc) and its hs-410 to treat bladder cancer. Show More
Quarter analysis & expected interest

There is not enough data for NightHawk Biosciences -stock to provide analysis

Correlation between past revenue and NightHawk Biosciences -stock search interest

There is not enough data for NightHawk Biosciences -stock to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for NightHawk Biosciences -stock to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for NightHawk Biosciences news to provide analysis

Correlation between past revenue and NightHawk Biosciences news search interest

There is not enough data for NightHawk Biosciences news to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for NightHawk Biosciences news to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ANTHIM obiltoxaximab to provide analysis

Correlation between past revenue and ANTHIM obiltoxaximab search interest

There is not enough data for ANTHIM obiltoxaximab to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ANTHIM obiltoxaximab to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for inhalational anthrax treatment to provide analysis

Correlation between past revenue and inhalational anthrax treatment search interest

There is not enough data for inhalational anthrax treatment to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for inhalational anthrax treatment to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 07 2024 22:37:56.

After 38 days of this quarter the interest is at 72.0. Based on that we can calculate that during remaining 53 days it will total up to 172.0.
medical countermeasures expected interest is significantly higher compared to previous quarter (+149.3%) but similar to same quarter last year.

YearQ1Q2Q3Q4
2019149
95
-36.2% QoQ
116
22.1% QoQ
163
40.5% QoQ
2020 89
-40.3% YoY -45.4% QoQ
90
-5.3% YoY 1.1% QoQ
168
44.8% YoY 86.7% QoQ
57
-65.0% YoY -66.1% QoQ
2021 90
1.1% YoY 57.9% QoQ
127
41.1% YoY 41.1% QoQ
72
-57.1% YoY -43.3% QoQ
71
24.6% YoY -1.4% QoQ
2022 285
216.7% YoY 301.4% QoQ
264
107.9% YoY -7.4% QoQ
178
147.2% YoY -32.6% QoQ
155
118.3% YoY -12.9% QoQ
2023 148
-48.1% YoY -4.5% QoQ
149
-43.6% YoY 0.7% QoQ
224
25.8% YoY 50.3% QoQ
69
-55.5% YoY -69.2% QoQ
2024 72
-51.4% YoY 4.3% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and medical countermeasures search interestLast update: February 07 2024 22:37:56.
Correlation coefficient between keyword and revenue is 0.94
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 07 2024 22:37:58.

The average 5 years interest of medical countermeasures was 10.89 per week.
The last year interest of medical countermeasures compared to the last 5 years has changed by 6.34%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by -1.61%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for NightHawk Biosciences products to provide analysis

Correlation between past revenue and NightHawk Biosciences products search interest

There is not enough data for NightHawk Biosciences products to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for NightHawk Biosciences products to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for NightHawk Biosciences contact to provide analysis

Correlation between past revenue and NightHawk Biosciences contact search interest

There is not enough data for NightHawk Biosciences contact to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for NightHawk Biosciences contact to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for NightHawk Biosciences location to provide analysis

Correlation between past revenue and NightHawk Biosciences location search interest

There is not enough data for NightHawk Biosciences location to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for NightHawk Biosciences location to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for NightHawk Biosciences executives to provide analysis

Correlation between past revenue and NightHawk Biosciences executives search interest

There is not enough data for NightHawk Biosciences executives to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for NightHawk Biosciences executives to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for NHWK
Earnings date: 2024-03-29 After close
Company name: NightHawk Biosciences Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2024-03-19T12:30:00Z

GlobeNewswire
Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University

2024-03-14T12:30:00Z

GlobeNewswire
Scorpius Holdings Accepted as a Member of the US Government's BioMaP-Consortium

2024-03-12T21:00:59Z

GlobeNewswire
Scorpius Holdings, Inc. Announces Closing of Public Offering

2024-03-08T05:20:00Z

GlobeNewswire
Scorpius Holdings, Inc. Announces Pricing of Public Offering

2024-03-07T21:18:08Z

GlobeNewswire
Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock

2024-03-07T13:30:00Z

GlobeNewswire
Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023

2024-02-06T09:34:04-05:00

SEC
8-K Form - Current report, items 5.03, 7.01, 8.01, and 9.01 - Scorpius Holdings, Inc. (0001476963) (Filer)

2024-02-06T13:00:00Z

GlobeNewswire
NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under "SCPX" Effective at the Market Open Today

2024-02-01T13:00:00Z

GlobeNewswire
NightHawk's Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating Officer

2024-01-30T08:00:09-05:00

SEC
8-K Form - Current report, items 1.01, 2.03, 3.02, 7.01, and 9.01 - NightHawk Biosciences, Inc. (0001476963) (Filer)

2024-01-30T13:00:00Z

GlobeNewswire
NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note

2024-01-26T16:30:14-05:00

SEC
8-K Form - Current report, items 8.01 and 9.01 - NightHawk Biosciences, Inc. (0001476963) (Filer)

2024-01-25T13:30:00Z

GlobeNewswire
NightHawk's Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program

2024-01-22T08:00:09-05:00

SEC
8-K Form - Current report, items 8.01 and 9.01 - NightHawk Biosciences, Inc. (0001476963) (Filer)

2024-01-16T08:30:09-05:00

SEC
8-K Form - Current report, items 7.01, 8.01, and 9.01 - NightHawk Biosciences, Inc. (0001476963) (Filer)